Pan-RAS Molecular Glue Safely Treats Lung, Pancreatic Cancers

European Organisation for Research and Treatment of Cancer

Barcelona, Spain: Results from the AURORAS-1 phase I clinical trial of an anti-cancer drug called ERAS-0015 have shown that it is safe and has caused tumours to shrink in hard-to-treat disease such as lung and pancreatic cancer.

Presented today (Friday) at the 38th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the findings from 148 patients are significant because ERAS-0015 targets tumours whose growth is driven by mutations in the RAS gene. Until recently, it was not thought possible to design drugs that could target these mutations successfully.

Dr Judy Wang, a medical oncologist at Florida Cancer Specialists and Research Institute, Sarasota, USA, told the Symposium: "AURORAS-1 has enrolled patients that have tried a number of other treatments for their cancer. In this context, ERAS-0015 treatment caused a 44% response rate in patients with RAS-mutant pancreatic cancer and a 60% response rate in patients with RAS-mutant lung cancer. A 'response' means the patients experienced considerable tumour shrinkage, and these response rates are important as they show clinically meaningful activity from ERAS-0015 treatment in patient groups that have few if any therapeutic options to address their cancer. In addition to this, ERAS-0015 was well tolerated with few severe side effects."

ERAS-0015 is a 'pan-RAS molecular glue', which means that it brings proteins together at the molecular level in a way that blocks tumour growth signals from several different cancer-driving RAS mutations. Certain RAS mutations work like a switch that is locked in the 'on' position, continuously conveying signals that lead to and sustain cancer. ERAS-0015 is designed to bind to the RAS 'switch' while it is in the 'on' state and thereby blocks those signals.

"The overall goal of precision oncology is to match a patient's mutation, or the 'Achilles Heel' of a specific individual's cancer, to a drug that directly targets that mutation. This is what we are attempting to do by studying the effectiveness of ERAS-0015 in patients with RAS alterations," said Dr Wang.

The AURORAS-1 trial started in June 2025 and is evaluating ERAS-0015 on its own and in combination with other anti-cancer therapies in people living with several types of RAS-mutant solid tumours. Enrolled patients have non-small cell lung (NSCLC) that has started to spread beyond the site of the primary tumour (locally advanced or metastatic), pancreatic cancer, colorectal (bowel) cancer and other solid tumours.

The results presented today were for 83 patients with pancreatic cancer and 37 with NSCLC; the trial is continuing to enrol patients.

Doses of ERAS-0015 started at 2 mg and increased up to 40 mg. During an average (median) follow-up period of just over four months, there was no sign that the maximum tolerated dose had been reached. Tumours shrank in eleven of 25 patients (44%) with pancreatic cancer who received 32 mg of ERAS-0015, and who had been previously treated with chemotherapy. Tumours shrank in three of five patients (60%) with lung cancer who received 32 mg and who had been treated previously with an immune checkpoint inhibitor or platinum-based chemotherapy.

The most common adverse side effects at doses of 16-32 mg in 10% or more of patients were rash, diarrhoea, nausea and inflammation of the lining of the mouth. Twelve patients (9.8%) reported severe (grade 3 or higher) treatment-related side effects. No side effects limited the drug doses.

"We are encouraged by the preliminary clinical activity and tolerability of ERAS-0015 in patients that have tried a number of other treatments for RAS-driven lung and pancreatic cancer," said Dr Wang.

"Our goal is to give clinicians new, better options for treating their patients with RAS-driven cancers. Early results suggest ERAS-0015 has the potential to be one of these options."

Limitations of the study are those associated with phase I clinical trials that always include only a limited number of patients. Further study in greater numbers of patients and in phase II and phase III clinical trials are needed to confirm the safety and efficacy of ERAS-0015.

"If these early results are confirmed, ERAS-0015 could offer patients with RAS-driven cancers a new option. Clinical development of ERAS-0015 would be impossible without the patients, caregivers, investigators and participating trial centres that put their trust in us to take part in our study. We are deeply grateful for their contribution to AURORAS-1," she concluded.

Professor Elena Garralda, chair of the EORTC-NCI-AACR Symposium and co-director of the Vall d'Hebron Institute of Oncology's clinical research programme, was not involved with the study. She commented: "This is the first presentation of these preliminary results from the AURORAS-1 clinical trial and they have been eagerly awaited. They show that the RAS inhibitor, ERAS-0015, has encouraging anti-tumour activity in cancers that are hard to treat successfully and for which there are few treatment options available. We look forward to further results from larger clinical trials, which are investigating whether ERAS-0015 can help a broader group of patients.

"This is one of several studies being presented at the EORTC-NCI-AACR Symposium that are beginning to show it is possible to design drugs that target cancers driven by RAS mutations, which was not thought possible until recently."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.